Literature DB >> 25682035

High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.

Bin Dong1, Amar Bahadur Singh1, Salman Azhar1, Nabil G Seidah2, Jingwen Liu3.   

Abstract

BACKGROUND: High fructose diet (HFD) induces dyslipidemia and insulin resistance in experimental animals and humans with incomplete mechanistic understanding. By utilizing mice and hamsters as in vivo models, we investigated whether high fructose consumption affects serum PCSK9 and liver LDL receptor (LDLR) protein levels.
RESULTS: Feeding mice with an HFD increased serum cholesterol and reduced serum PCSK9 levels as compared with the mice fed a normal chow diet (NCD). In contrast to the inverse relationship in mice, serum PCSK9 and cholesterol levels were co-elevated in HFD-fed hamsters. Liver tissue analysis revealed that PCSK9 mRNA and protein levels were both reduced in mice and hamsters by HFD feeding, however, liver LDLR protein levels were markedly reduced by HFD in hamsters but not in mice. We further showed that circulating PCSK9 clearance rates were significantly lower in hamsters fed an HFD as compared with the hamsters fed NCD, providing additional evidence for the reduced hepatic LDLR function by HFD consumption. The majority of PCSK9 in hamster serum was detected as a 53 kDa N-terminus cleaved protein. By conducting in vitro studies, we demonstrate that this 53 kDa truncated hamster PCSK9 is functionally active in promoting hepatic LDLR degradation.
CONCLUSION: Our studies for the first time demonstrate that high fructose consumption increases serum PCSK9 concentrations and reduces liver LDLR protein levels in hyperlipidemic hamsters. The positive correlation between circulating cholesterol and PCSK9 and the reduction of liver LDLR protein in HFD-fed hamsters suggest that hamster is a better animal model than mouse to study the modulation of PCSK9/LDLR pathway by atherogenic diets. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Dyslipidemia; Hamsters; High fructose diet; LDL receptor; PCSK9

Mesh:

Substances:

Year:  2015        PMID: 25682035      PMCID: PMC4523098          DOI: 10.1016/j.atherosclerosis.2015.01.013

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  44 in total

1.  The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.

Authors:  Suzanne Benjannet; David Rhainds; Josée Hamelin; Nasha Nassoury; Nabil G Seidah
Journal:  J Biol Chem       Date:  2006-08-15       Impact factor: 5.157

Review 2.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

3.  Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.

Authors:  Mark J Graham; Kristina M Lemonidis; Charles P Whipple; Amuthakannan Subramaniam; Brett P Monia; Stanley T Crooke; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2007-01-22       Impact factor: 5.922

4.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

5.  Anti-diabetic effects of the ethanol extract of a functional formula diet in mice fed with a fructose/fat-rich combination diet.

Authors:  Qian Cheng; Xiaofeng Zhang; Ou Wang; Jia Liu; Shengbao Cai; Ruojun Wang; Feng Zhou; Baoping Ji
Journal:  J Sci Food Agric       Date:  2014-06-24       Impact factor: 3.638

Review 6.  Metabolic effects of fructose and the worldwide increase in obesity.

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

7.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Authors:  Hua Sun; Amin Samarghandi; Ningyan Zhang; Zemin Yao; Momiao Xiong; Ba-Bie Teng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-10       Impact factor: 8.311

9.  LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.

Authors:  Noam Zelcer; Cynthia Hong; Rima Boyadjian; Peter Tontonoz
Journal:  Science       Date:  2009-06-11       Impact factor: 47.728

Review 10.  Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease.

Authors:  Artemis P Simopoulos
Journal:  Nutrients       Date:  2013-07-26       Impact factor: 5.717

View more
  8 in total

1.  Calorically restricted diets decrease PCSK9 in overweight adolescents.

Authors:  A E Levenson; C E Milliren; S B Biddinger; C B Ebbeling; H A Feldman; D S Ludwig; S D de Ferranti
Journal:  Nutr Metab Cardiovasc Dis       Date:  2017-01-03       Impact factor: 4.222

2.  Ramadan Intermittent Fasting Is Associated with Changes in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Metabolically Healthy Obese Subjects.

Authors:  Hayder Hasan; Mohamed Madkour; Samir Awadallah; Mohamed Hassanein; Haitham Jahrami; MoezAlIslam Faris
Journal:  Medicina (Kaunas)       Date:  2022-03-31       Impact factor: 2.948

Review 3.  High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions.

Authors:  Dong-Mei Zhang; Rui-Qing Jiao; Ling-Dong Kong
Journal:  Nutrients       Date:  2017-03-29       Impact factor: 5.717

Review 4.  Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease.

Authors:  Kasper W Ter Horst; Mireille J Serlie
Journal:  Nutrients       Date:  2017-09-06       Impact factor: 5.717

Review 5.  The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

Authors:  Nabil G Seidah
Journal:  Glob Cardiol Sci Pract       Date:  2017-03-31

Review 6.  Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Authors:  Simon Glerup; Rainer Schulz; Ulrich Laufs; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165

7.  Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.

Authors:  Sheng-Hua Yang; Rui-Xia Xu; Chuan-Jue Cui; Yin Wang; Ying Du; Zhi-Guo Chen; Yu-Hong Yao; Chun-Yan Ma; Cheng-Gang Zhu; Yuan-Lin Guo; Na-Qiong Wu; Jing Sun; Bu-Xing Chen; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2018-04-04       Impact factor: 9.951

8.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.